同種細胞治療市場：タイプ、応用、最終用途別-2024～2030年の世界予測

同種細胞治療の市場規模は2023年に20億4,000万米ドルと推計され、2024年には23億1,000万米ドルに達し、CAGR 13.90％で2030年には50億8,000万米ドルに達すると予測されています。

同種細胞治療では、特定のがん、自己免疫疾患、心臓疾患など様々な疾患の治療に役立てるため、健康なドナー1人から複数の患者に細胞を移植する医療処置が行われています。遺伝子工学、細胞加工、培養技術の進歩により、同種細胞治療の有効性と安全性が大幅に向上し、市場の成長に拍車をかけています。がん、自己免疫疾患、心血管疾患の世界の罹患率の増加が、同種細胞治療のような革新的な治療法に対する需要を牽引しています。世界的に政府の政策が好意的であり、細胞ベースの治療法の研究への資金援助が増加していることが、市場の拡大を加速させています。しかし、同種細胞治療の開発・投与に伴う高額なコストは、より幅広い患者層へのアクセスを制限しています。免疫拒絶反応や副作用回避のための免疫抑制剤の必要性は、市場成長にとって依然として大きな課題です。さらに、細胞の調達、保存、拡張性の向上を目指した継続的な研究が、市場成長の大きな機会となっています。個々の患者のプロファイルに合わせた同種細胞治療ソリューションを開発することで、個別化医療への新たな道が開けるかもしれません。

タイプ抗炎症作用と免疫調節作用により間葉系幹細胞治療の採用が拡大

キメラ抗原受容体T細胞療法（CAR-T）は、がん細胞を特異的に標的とするキメラ抗原受容体のイントロダクションであり、がん治療に個別化アプローチを提供します。CAR-T細胞療法は、主に非ホジキンリンパ腫や急性リンパ芽球性白血病を含む特定の種類の血液がんに採用され、治療成績を向上させています。造血幹細胞移植は、損傷した骨髄を健康な幹細胞と置き換えるために、ドナー（同種）からの幹細胞の移植を担当します。造血幹細胞移植は、特定の白血病、リンパ腫、遺伝性血液疾患の患者に対して、他の治療法が有効でない場合、治療計画の一部として選択される治療法です。人工多能性幹細胞療法（iPSC）は、皮膚細胞や血液細胞を胚のような多能性の状態に再プログラムしたものです。iPSC技術は主に再生医療、疾患モデル、創薬に利用されています。間葉系幹細胞治療は、様々な細胞型に分化する能力を持ち、抗炎症作用や免疫調節作用を有します。

用途：同種細胞治療と臓器移植手順の改善における役割に革命を起こす

同種細胞治療は、白血病やリンパ腫などの血液疾患の治療を大きく改善しました。オンコロジー治療では、同種細胞治療は、がん細胞を攻撃する免疫システムの能力を活用し、さまざまながんとの闘いに利用されています。

再生医療は同種細胞治療の最もエキサイティングな分野であり、人間の細胞、臓器、組織を修復、置換、再生し、正常な機能を回復させることに焦点を当てています。同種細胞治療はまた、固形臓器移植、特に移植拒絶反応のリスクと生涯にわたる免疫抑制の必要性を軽減する上で、極めて重要な役割を果たしています。

地域別の洞察

南北アメリカ、特に米国とカナダは、堅調な投資、最先端の研究、バイオテクノロジーの技術革新をますます促進する支援的な規制環境に牽引され、同種細胞治療産業の最前線に位置しています。細胞加工技術やバイオリアクターの設計に関する特許の着実な取得に代表される知的財産の発展は、南北アメリカ地域の市場の活気を示しています。欧州連合（EU）では、同種細胞治療を含め、再生医療に対する政府と民間の強力な支援が行われています。ドイツ、英国、フランスなどの国々は特に活発で、数多くの臨床試験や研究イニシアチブを実施しており、また患者の安全性を確保しながらイノベーションを奨励する規制の枠組みからも恩恵を受けています。アラブ首長国連邦やサウジアラビアなどの中東諸国は、ヘルスケア・インフラに多額の投資を行っており、細胞治療を含む先進医療の導入に関心を示しています。アフリカ地域はより多様であり、南アフリカは再生医療に関する研究と関心の点でリードしています。アジア太平洋地域では、中国がバイオテクノロジー研究に対する政府の実質的な支援を受けて目覚ましい発展を遂げています。日本とインドは、有望な治療法を迅速に進めるための有利な規制政策に支えられ、再生医療の先駆者として定評があります。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは同種細胞治療市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、同種細胞治療市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された蓄積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.同種細胞治療市場の市場規模および予測は？

2.同種細胞治療市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.同種細胞治療市場の技術動向と規制枠組みは？

4.同種細胞治療市場における主要ベンダーの市場シェアは？

5.同種細胞治療市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • がん、自己免疫疾患、心血管疾患の発生率の増加
    • 細胞ベースの治療法の調査に対する政府の好ましい政策と資金の増加
  • 抑制要因
    • 同種細胞治療の開発と管理に関する複雑な規制環境
  • 機会
    • パーソナライズされた同種細胞治療ソリューションの開発
    • 神経変性疾患および心臓疾患における新たな治療法の探究
  • 課題
    • 免疫拒絶と適合性の問題
• 市場セグメンテーション分析
  • タイプ：抗炎症作用と免疫調節作用による間葉系幹細胞療法の採用増加
  • 応用：臓器移植の治療と改善における同種細胞治療の役割を革新する
• 市場ディスラプション分析
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 価格分析
• 技術分析
• 特許分析
• 貿易分析
• 規制枠組みの分析

第6章 同種細胞治療市場：タイプ別

• キメラ抗原受容体T細胞療法
• 造血幹細胞移植
• 人工多能性幹細胞療法
• 間葉系幹細胞療法

第7章 同種細胞治療市場：応用別

• 血液疾患
• 腫瘍学
• 再生医療
• 固形臓器移植

第8章 同種細胞治療市場：最終用途別

• バイオテクノロジーおよび製薬会社
• 病院・クリニック
• 調査機関

第9章 南北アメリカの同種細胞治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の同種細胞治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの同種細胞治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析（2023年）
• FPNVポジショニングマトリックス（2023年）
• 競合シナリオ分析
  • GetingeとCellRevの戦略的提携で製造業に革命を起こす
  • StemCyteの画期的な臍帯血由来細胞療法への世界のアクセスを促進する先駆的な契約
  • Gamida Cellのオミシルゲ療法が血液がん治療の画期的進歩としてFDAに承認
• 戦略分析と提言

第13章 競争力のあるポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. ALLOGENEIC CELL THERAPY MARKET RESEARCH PROCESS
• FIGURE 2. ALLOGENEIC CELL THERAPY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. ALLOGENEIC CELL THERAPY MARKET DYNAMICS
• FIGURE 7. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 14. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 16. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. ALLOGENEIC CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 22. ALLOGENEIC CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ALLOGENEIC CELL THERAPY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELL THERAPY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELL THERAPY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL THERAPY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL THERAPY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 36. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 37. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 38. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 39. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 40. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 41. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 42. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 43. ARGENTINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 44. ARGENTINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 45. ARGENTINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 46. ARGENTINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 47. ARGENTINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 48. ARGENTINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 49. BRAZIL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 50. BRAZIL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 51. BRAZIL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 52. BRAZIL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 53. BRAZIL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 54. BRAZIL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 55. CANADA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 56. CANADA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 57. CANADA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 58. CANADA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 59. CANADA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 60. CANADA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 61. MEXICO ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 62. MEXICO ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 63. MEXICO ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 64. MEXICO ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 65. MEXICO ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 66. MEXICO ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 67. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 68. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 69. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 70. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 71. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 72. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 73. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 74. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 75. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 76. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 77. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 78. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 79. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 80. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 81. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 82. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 83. AUSTRALIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 84. AUSTRALIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 85. AUSTRALIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 86. AUSTRALIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 87. AUSTRALIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 88. AUSTRALIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 89. CHINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 90. CHINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 91. CHINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 92. CHINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 93. CHINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 94. CHINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 95. INDIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 96. INDIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 97. INDIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 98. INDIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 99. INDIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 100. INDIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 101. INDONESIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 102. INDONESIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 103. INDONESIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 104. INDONESIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 105. INDONESIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 106. INDONESIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 107. JAPAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 108. JAPAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 109. JAPAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 110. JAPAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 111. JAPAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 112. JAPAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 113. MALAYSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 114. MALAYSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 115. MALAYSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 116. MALAYSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 117. MALAYSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 118. MALAYSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 119. PHILIPPINES ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 120. PHILIPPINES ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 121. PHILIPPINES ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 122. PHILIPPINES ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 123. PHILIPPINES ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 124. PHILIPPINES ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 125. SINGAPORE ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 126. SINGAPORE ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 127. SINGAPORE ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 128. SINGAPORE ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 129. SINGAPORE ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 130. SINGAPORE ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 131. SOUTH KOREA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 132. SOUTH KOREA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 133. SOUTH KOREA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 134. SOUTH KOREA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 135. SOUTH KOREA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 136. SOUTH KOREA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 137. TAIWAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 138. TAIWAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 139. TAIWAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 140. TAIWAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 141. TAIWAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 142. TAIWAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 143. THAILAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 144. THAILAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 145. THAILAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 146. THAILAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 147. THAILAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 148. THAILAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 149. VIETNAM ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 150. VIETNAM ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 151. VIETNAM ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 152. VIETNAM ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 153. VIETNAM ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 154. VIETNAM ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 157. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 158. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 159. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 160. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 161. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 162. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 163. DENMARK ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 164. DENMARK ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 165. DENMARK ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 166. DENMARK ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 167. DENMARK ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 168. DENMARK ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 169. EGYPT ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 170. EGYPT ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 171. EGYPT ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 172. EGYPT ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 173. EGYPT ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 174. EGYPT ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 175. FINLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 176. FINLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 177. FINLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 178. FINLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 179. FINLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 180. FINLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 181. FRANCE ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 182. FRANCE ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 183. FRANCE ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 184. FRANCE ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 185. FRANCE ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 186. FRANCE ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 187. GERMANY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 188. GERMANY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 189. GERMANY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 190. GERMANY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 191. GERMANY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 192. GERMANY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 193. ISRAEL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 194. ISRAEL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 195. ISRAEL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 196. ISRAEL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 197. ISRAEL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 198. ISRAEL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 199. ITALY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 200. ITALY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 201. ITALY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 202. ITALY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 203. ITALY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 204. ITALY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 205. NETHERLANDS ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 206. NETHERLANDS ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 207. NETHERLANDS ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 208. NETHERLANDS ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 209. NETHERLANDS ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 210. NETHERLANDS ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 211. NIGERIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 212. NIGERIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 213. NIGERIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 214. NIGERIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 215. NIGERIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 216. NIGERIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 217. NORWAY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 218. NORWAY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 219. NORWAY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 220. NORWAY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 221. NORWAY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 222. NORWAY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 223. POLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 224. POLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 225. POLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 226. POLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 227. POLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 228. POLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 229. QATAR ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 230. QATAR ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 231. QATAR ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 232. QATAR ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 233. QATAR ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 234. QATAR ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 235. RUSSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 236. RUSSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 237. RUSSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 238. RUSSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 239. RUSSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 240. RUSSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 241. SAUDI ARABIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 242. SAUDI ARABIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 243. SAUDI ARABIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 244. SAUDI ARABIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 245. SAUDI ARABIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 246. SAUDI ARABIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 247. SOUTH AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 248. SOUTH AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 249. SOUTH AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 250. SOUTH AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 251. SOUTH AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 252. SOUTH AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 253. SPAIN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 254. SPAIN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 255. SPAIN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 256. SPAIN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 257. SPAIN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 258. SPAIN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 259. SWEDEN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 260. SWEDEN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 261. SWEDEN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 262. SWEDEN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 263. SWEDEN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 264. SWEDEN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 265. SWITZERLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 266. SWITZERLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 267. SWITZERLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 268. SWITZERLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 269. SWITZERLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 270. SWITZERLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 271. TURKEY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 272. TURKEY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 273. TURKEY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 274. TURKEY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 275. TURKEY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 276. TURKEY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 277. UNITED ARAB EMIRATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 278. UNITED ARAB EMIRATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 279. UNITED ARAB EMIRATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 280. UNITED ARAB EMIRATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 281. UNITED ARAB EMIRATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 282. UNITED ARAB EMIRATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 283. UNITED KINGDOM ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 284. UNITED KINGDOM ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 285. UNITED KINGDOM ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 286. UNITED KINGDOM ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 287. UNITED KINGDOM ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 288. UNITED KINGDOM ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 289. ALLOGENEIC CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 290. ALLOGENEIC CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

[187 Pages Report] The Allogeneic Cell Therapy Market size was estimated at USD 2.04 billion in 2023 and expected to reach USD 2.31 billion in 2024, at a CAGR 13.90% to reach USD 5.08 billion by 2030.

Allogeneic cell therapy involves medical treatments wherein cells are transferred from a single healthy donor to multiple patients to help treat various diseases, including certain cancers, autoimmune diseases, and heart conditions. Ongoing advances in genetic engineering, cell processing, and culturing techniques have significantly enhanced the efficacy and safety of allogeneic cell therapies, fueling market growth. The growing incidence of cancers, autoimmune diseases, and cardiovascular conditions globally drives the demand for innovative treatments such as allogeneic cell therapy. Favorable government policies worldwide and increased funding for research in cell-based therapies have accelerated market expansion. However, high costs associated with the development and administration of allogeneic cell therapies limit accessibility for a broader patient base. Immune rejection and the need for immunosuppressants to avoid adverse reactions remain significant challenges for market growth. Moreover, continuous research aiming at improving cell sourcing, preservation, and scalability presents substantial opportunities for market growth. Developing tailored allogeneic cell therapy solutions catering to individual patient profiles may open new avenues for personalized medicine.

Type: Growing adoption of mesenchymal stem cell therapy due to anti-inflammatory and immunomodulatory properties

Chimeric antigen receptor T cell therapy (CAR-T) involves the introduction of a chimeric antigen receptor that specifically targets cancer cells, providing a personalized approach to cancer therapy. CAR-T cell therapy is primarily employed for certain types of blood cancers including non-Hodgkin lymphoma and acute lymphoblastic leukemia for improved outcomes. Hematopoietic stem cell transplantation is responsible for the transplantation of stem cells from a donor (allogeneic) to replace damaged bone marrow with healthy stem cells. Hematopoietic stem cell transplantation is the treatment of choice for patients with certain leukemias, lymphomas, and genetic blood disorders when other treatments are not effective or as a part of the treatment plan. Induced pluripotent stem cell therapy (iPSC) is derived from skin or blood cells reprogrammed back into an embryonic-like pluripotent state. iPSC technology is primarily utilized for regenerative medicine, disease modeling, and drug discovery. Mesenchymal stem cell therapy has the ability to differentiate into various cell types and possesses anti-inflammatory and immunomodulatory properties.

Application: Revolutionizing allogeneic cell therapy's role in treating and improving organ transplantation procedures

Allogeneic cell therapy has significantly improved the treatment of hematological disorders, such as leukemia and lymphoma. In oncology therapies, allogeneic cell therapy is utilized to fight against various cancer forms, leveraging the immune system's capacity to attack cancer cells.

Regenerative medicine represents the most exciting areas of allogeneic cell therapy, focusing on repairing, replacing, and regenerating human cells, organs, or tissues to restore normal function. Allogeneic cell therapy also plays a pivotal role in solid organ transplantation, particularly in reducing the risk of transplant rejection and the need for lifelong immunosuppression.

Regional Insights

The Americas, particularly the United States and Canada, are at the forefront of the allogeneic cell therapy industry, driven by robust investments, cutting-edge research, and a supportive regulatory environment that is increasingly conducive to innovation in biotechnology. Intellectual property developments, typified by a steady stream of patents related to cell processing techniques and bioreactor designs, demonstrate the vibrancy of the market in the Americas region. The European Union observes strong government and private support for regenerative medicine, including allogeneic cell therapy. Countries such as Germany, the United Kingdom, and France have been particularly active, with numerous clinical trials and research initiatives, and also benefit from a regulatory framework encouraging innovation while ensuring patient safety. Middle East countries such as the United Arab Emirates and Saudi Arabia, are investing significantly in healthcare infrastructure and have shown interest in adopting advanced medical treatments, including cell therapies. The African region is more diverse, with South Africa leading in terms of research and interest in regenerative medicine. In the APAC region, China has made remarkable strides, with substantial government backing for biotechnology research. Japan and India have a well-established reputation for pioneering regenerative medicine, supported by favorable regulatory policies to fast-track promising therapies.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Allogeneic Cell Therapy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Allogeneic Cell Therapy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Allogeneic Cell Therapy Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., AlloSource, Anterogen.Co., Ltd., Atara Biotherapeutics by FUJIFILM Diosynth Biotechnologies, Athersys Inc., Biorestorative Therapies Inc., Biosolution Co., Ltd., Bloodworks Northwest, Brainstorm Cell Limited, Caribou Biosciences, Fate Therapeutics, Gamida Cell, Hope Biosciences, JCR Pharmaceuticals Co., Ltd., Mallinckrodt Pharmaceuticals, MEDIPOST Co., Ltd., Mesoblast Ltd., NuVasive Inc. by Globus Medical, RTI Surgical, Smith+Nephew PLC, Stempeutics Research Pvt. Ltd., Sumitomo Pharma Co., Ltd., Takeda Pharmaceutical Company Limited, Tego Science Inc., and ViaCyte Inc. by Vertex Pharmaceuticals.

Market Segmentation & Coverage

This research report categorizes the Allogeneic Cell Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Type
  • Chimeric Antigen Receptor T Cell Therapy
  • Hematopoietic Stem Cell Transplantation
  • Induced Pluripotent Stem Cell Therapy
  • Mesenchymal Stem Cell Therapy

• Application
  • Hematological Disorders
  • Oncology
  • Regenerative Medicine
  • Solid Organ Transplantation

• End-Use
  • Biotechnology & Pharmaceutical Companies
  • Hospitals & Clinics
  • Research Institutes

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Allogeneic Cell Therapy Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Allogeneic Cell Therapy Market?

3. What are the technology trends and regulatory frameworks in the Allogeneic Cell Therapy Market?

4. What is the market share of the leading vendors in the Allogeneic Cell Therapy Market?

5. Which modes and strategic moves are suitable for entering the Allogeneic Cell Therapy Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing incidences of cancers, autoimmune diseases, and cardiovascular conditions
    • 5.1.1.2. Favorable government policies and increased funding for research in cell-based therapies
  • 5.1.2. Restraints
    • 5.1.2.1. Complex regulatory environment for development and administration of allogeneic cell therapies
  • 5.1.3. Opportunities
    • 5.1.3.1. Development of personalized allogeneic cell therapy solutions
    • 5.1.3.2. Exploration into the new treatment avenues in neurodegenerative diseases and cardiac diseases
  • 5.1.4. Challenges
    • 5.1.4.1. Immune rejection and compatibility issues
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Growing adoption of mesenchymal stem cell therapy due to anti-inflammatory and immunomodulatory properties
  • 5.2.2. Application: Revolutionizing allogeneic cell therapy's role in treating and improving organ transplantation procedures
• 5.3. Market Disruption Analysis
• 5.4. Porter's Five Forces Analysis
  • 5.4.1. Threat of New Entrants
  • 5.4.2. Threat of Substitutes
  • 5.4.3. Bargaining Power of Customers
  • 5.4.4. Bargaining Power of Suppliers
  • 5.4.5. Industry Rivalry
• 5.5. Value Chain & Critical Path Analysis
• 5.6. Pricing Analysis
• 5.7. Technology Analysis
• 5.8. Patent Analysis
• 5.9. Trade Analysis
• 5.10. Regulatory Framework Analysis

6. Allogeneic Cell Therapy Market, by Type

• 6.1. Introduction
• 6.2. Chimeric Antigen Receptor T Cell Therapy
• 6.3. Hematopoietic Stem Cell Transplantation
• 6.4. Induced Pluripotent Stem Cell Therapy
• 6.5. Mesenchymal Stem Cell Therapy

7. Allogeneic Cell Therapy Market, by Application

• 7.1. Introduction
• 7.2. Hematological Disorders
• 7.3. Oncology
• 7.4. Regenerative Medicine
• 7.5. Solid Organ Transplantation

8. Allogeneic Cell Therapy Market, by End-Use

• 8.1. Introduction
• 8.2. Biotechnology & Pharmaceutical Companies
• 8.3. Hospitals & Clinics
• 8.4. Research Institutes

9. Americas Allogeneic Cell Therapy Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Allogeneic Cell Therapy Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Allogeneic Cell Therapy Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Getinge's Strategic Partnership with CellRev to Revolutionize Allogeneic Cell Therapy Manufacturing
  • 12.3.2. StemCyte's Pioneering Agreement for Advancing Worldwide Access to Groundbreaking Cord Blood-Derived Cell Therapies
  • 12.3.3. FDA Approval of Gamida Cell's Omisirge Therapy as Transformative Leap in Hematological Cancer Treatment
• 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

• 13.1. Key Company Profiles
• 13.2. Key Product Portfolio